Table 1 Checklist of items to include when reporting a study developing or validating a multivariable prediction model for diagnosis or prognosisa
Section/topic | Item | Development or validation? | Checklist item | Page |
---|---|---|---|---|
Title and abstract | ||||
Title | 1 | D;V | Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted. | Â |
Abstract | 2 | D;V | Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions. | Â |
Introduction | ||||
Background and objectives | 3a | D;V | Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models. | Â |
 | 3b | D;V | Specify the objectives, including whether the study describes the development or validation of the model, or both. |  |
Methods | ||||
Source of data | 4a | D;V | Describe the study design or source of data (e.g., randomised trial, cohort, or registry data), separately for the development and validation data sets, if applicable. | Â |
 | 4b | D;V | Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up. |  |
Participants | 5a | D;V | Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and ___location of centres. | Â |
 | 5b | D;V | Describe eligibility criteria for participants. |  |
 | 5c | D;V | Give details of treatments received, if relevant. |  |
Outcome | 6a | D;V | Clearly define the outcome that is predicted by the prediction model, including how and when assessed. | Â |
 | 6b | D;V | Report any actions to blind assessment of the outcome to be predicted. |  |
Predictors | 7a | D;V | Clearly define all predictors used in developing the multivariable prediction model, including how and when they were measured. | Â |
 | 7b | D;V | Report any actions to blind assessment of predictors for the outcome and other predictors. |  |
Sample size | 8 | D;V | Explain how the study size was arrived at. | Â |
Missing data | 9 | D;V | Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method. | Â |
Statistical analysis methods | 10a | D | Describe how predictors were handled in the analyses. | Â |
 | 10b | D | Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. |  |
 | 10c | V | For validation, describe how the predictions were calculated. |  |
 | 10d | D;V | Specify all measures used to assess model performance and, if relevant, to compare multiple models. |  |
 | 10e | V | Describe any model updating (e.g., recalibration) arising from the validation, if done. |  |
Risk groups | 11 | D;V | Provide details on how risk groups were created, if done. | Â |
Development vs validation | 12 | V | For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors. | Â |
Results | ||||
Participants | 13a | D;V | Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. | Â |
 | 13b | D;V | Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome. |  |
 | 13c | V | For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors, and outcome). |  |
Model development | 14a | D | Specify the number of participants and outcome events in each analysis. | Â |
 | 14b | D | If done, report the unadjusted association between each candidate predictor and outcome. |  |
Model specification | 15a | D | Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point). | Â |
 | 15b | D | Explain how to use the prediction model. |  |
Model performance | 16 | D;V | Report performance measures (with CIs) for the prediction model. | Â |
Model updating | 17 | V | If done, report the results from any model updating (i.e., model specification, model performance). | Â |
Discussion | ||||
Limitations | 18 | D;V | Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data). | Â |
Interpretation | 19a | V | For validation, discuss the results with reference to performance in the development data, and any other validation data. | Â |
 | 19b | D;V | Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence. |  |
Implications | 20 | D;V | Discuss the potential clinical use of the model and implications for future research | Â |
Other information | ||||
Supplementary information | 21 | D;V | Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. | Â |
Funding | 22 | D;V | Give the source of funding and the role of the funders for the present study. | Â |